Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: Latest evidence and clinical usefulness

Yoram Yagil, Stephen Z. Fadem, Kotagal S. Kant, Udayan Bhatt, Mohammed Sika, Julia B. Lewis, Dana Negoi

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Ferric citrate is a novel phosphate binder that allows the simultaneous treatment of hyperphosphatemia and iron deficiency in patients being treated for end-stage renal disease with hemodialysis (HD). Multiple clinical trials in HD patients have uniformly and consistently demonstrated the efficacy of the drug in controlling hyperphosphatemia with a good safety profile, leading the US Food and Drug Administration in 2014 to approve its use for that indication. A concurrent beneficial effect, while using ferric citrate as a phosphate binder, is its salutary effect in HD patients with iron deficiency being treated with an erythropoietin-stimulating agent (ESA) in restoring iron that becomes available for reversing chronic kidney disease (CKD)-related anemia. Ferric citrate has also been shown in several studies to diminish the need for intravenous iron treatment and to reduce the requirement for ESA. Ferric citrate is thus a preferred phosphate binder that helps resolve CKD-related mineral bone disease and iron-deficiency anemia.

Original languageEnglish
Pages (from-to)252-263
Number of pages12
JournalTherapeutic Advances in Chronic Disease
Volume6
Issue number5
DOIs
StatePublished - 1 Jan 2015
Externally publishedYes

Keywords

  • Efficacy
  • Ferric citrate
  • Hemodialysis
  • Hyperphosphatemia
  • Iron deficiency
  • Safety

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Fingerprint

Dive into the research topics of 'Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: Latest evidence and clinical usefulness'. Together they form a unique fingerprint.

Cite this